Cargando…
Enhancement of clonogenicity of human multiple myeloma by dendritic cells
Infiltration by dendritic cells (DCs) is a common feature of most human tumors. Prior studies evaluating the interaction of DCs with tumors have focused largely on their immunologic properties (for review see Banchereau, J., and R.M. Steinman. 1998. Nature. 392:245–252). In this study, we show that...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034506/ https://www.ncbi.nlm.nih.gov/pubmed/16880256 http://dx.doi.org/10.1084/jem.20052136 |
_version_ | 1782137015019503616 |
---|---|
author | Kukreja, Anjli Hutchinson, Aisha Dhodapkar, Kavita Mazumder, Amitabha Vesole, David Angitapalli, Revathi Jagannath, Sundar Dhodapkar, Madhav V. |
author_facet | Kukreja, Anjli Hutchinson, Aisha Dhodapkar, Kavita Mazumder, Amitabha Vesole, David Angitapalli, Revathi Jagannath, Sundar Dhodapkar, Madhav V. |
author_sort | Kukreja, Anjli |
collection | PubMed |
description | Infiltration by dendritic cells (DCs) is a common feature of most human tumors. Prior studies evaluating the interaction of DCs with tumors have focused largely on their immunologic properties (for review see Banchereau, J., and R.M. Steinman. 1998. Nature. 392:245–252). In this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC–tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)–RANK ligand and B cell–activating factor–APRIL (a proliferation-inducing ligand)-mediated interactions. Together, these data suggest that tumor–DC interactions may directly impact the biology of human tumors, particularly multiple myeloma, and may be a target for therapeutic intervention. |
format | Text |
id | pubmed-2034506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-20345062007-12-13 Enhancement of clonogenicity of human multiple myeloma by dendritic cells Kukreja, Anjli Hutchinson, Aisha Dhodapkar, Kavita Mazumder, Amitabha Vesole, David Angitapalli, Revathi Jagannath, Sundar Dhodapkar, Madhav V. J Exp Med Brief Definitive Reports Infiltration by dendritic cells (DCs) is a common feature of most human tumors. Prior studies evaluating the interaction of DCs with tumors have focused largely on their immunologic properties (for review see Banchereau, J., and R.M. Steinman. 1998. Nature. 392:245–252). In this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC–tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)–RANK ligand and B cell–activating factor–APRIL (a proliferation-inducing ligand)-mediated interactions. Together, these data suggest that tumor–DC interactions may directly impact the biology of human tumors, particularly multiple myeloma, and may be a target for therapeutic intervention. The Rockefeller University Press 2006-08-07 /pmc/articles/PMC2034506/ /pubmed/16880256 http://dx.doi.org/10.1084/jem.20052136 Text en Copyright © 2006, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Brief Definitive Reports Kukreja, Anjli Hutchinson, Aisha Dhodapkar, Kavita Mazumder, Amitabha Vesole, David Angitapalli, Revathi Jagannath, Sundar Dhodapkar, Madhav V. Enhancement of clonogenicity of human multiple myeloma by dendritic cells |
title | Enhancement of clonogenicity of human multiple myeloma by dendritic cells |
title_full | Enhancement of clonogenicity of human multiple myeloma by dendritic cells |
title_fullStr | Enhancement of clonogenicity of human multiple myeloma by dendritic cells |
title_full_unstemmed | Enhancement of clonogenicity of human multiple myeloma by dendritic cells |
title_short | Enhancement of clonogenicity of human multiple myeloma by dendritic cells |
title_sort | enhancement of clonogenicity of human multiple myeloma by dendritic cells |
topic | Brief Definitive Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034506/ https://www.ncbi.nlm.nih.gov/pubmed/16880256 http://dx.doi.org/10.1084/jem.20052136 |
work_keys_str_mv | AT kukrejaanjli enhancementofclonogenicityofhumanmultiplemyelomabydendriticcells AT hutchinsonaisha enhancementofclonogenicityofhumanmultiplemyelomabydendriticcells AT dhodapkarkavita enhancementofclonogenicityofhumanmultiplemyelomabydendriticcells AT mazumderamitabha enhancementofclonogenicityofhumanmultiplemyelomabydendriticcells AT vesoledavid enhancementofclonogenicityofhumanmultiplemyelomabydendriticcells AT angitapallirevathi enhancementofclonogenicityofhumanmultiplemyelomabydendriticcells AT jagannathsundar enhancementofclonogenicityofhumanmultiplemyelomabydendriticcells AT dhodapkarmadhavv enhancementofclonogenicityofhumanmultiplemyelomabydendriticcells |